Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43871   clinical trials with a EudraCT protocol, of which   7290   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2020-005263-31
    Sponsor's Protocol Code Number:LEVOKETO_02-2020
    National Competent Authority:Germany - BfArM
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2021-06-18
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedGermany - BfArM
    A.2EudraCT number2020-005263-31
    A.3Full title of the trial
    Assessment of the effects and tolerability of RD03/2016 (Levofloxacin; Ketorolac Trometamol 0.5+0.5% w/v eye drops solution) for the treatment of bacterial conjunctivitis in adults: a multicentre, randomized, blinded-assessor, phase II non-inferiority study - MIRAKLE
    Bewertung der Wirkungen und der Verträglichkeit von RD03/2016 (Levofloxacin; Ketorolac Trometamol 0,5 + 0,5 % Gew./Vol. Augentropfen, Lösung) zur Behandlung bakterieller Konjunktivitis bei Erwachsenen: eine multizentrische, randomisierte, prüferverblindete Nichtunterlegenheitsstudie der Phase II – MIRAKLE
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Assessment of the effects and tolerability of RD03/2016 eye drops for the treatment of bacterial conjunctivitis in adults
    Bewertung der Wirkungen und der Verträglichkeit von RD03/2016 Augentropfen zur Behandlung bakterieller Bindehautentzündung bei Erwachsenen_- MIRAKLE
    A.3.2Name or abbreviated title of the trial where available
    MIRAKLE
    A.4.1Sponsor's protocol code numberLEVOKETO_02-2020
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNTC s.r.l.
    B.1.3.4CountryItaly
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNTC s.r.l.
    B.4.2CountryItaly
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationOPIS s.r.l.
    B.5.2Functional name of contact pointDipartimento Medico
    B.5.3 Address:
    B.5.3.1Street AddressVia Matteotti, 10
    B.5.3.2Town/ cityDesio (MB)
    B.5.3.3Post code20832
    B.5.3.4CountryItaly
    B.5.4Telephone number0039 0362 633 1
    B.5.5Fax number0039 0362 633 633
    B.5.6E-mailosservatorio@opis.it
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameRD03/2016
    D.3.4Pharmaceutical form Eye drops, solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOcular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLEVOFLOXACIN
    D.3.9.1CAS number 100986-85-4
    D.3.9.4EV Substance CodeSUB08471MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNKETOROLAC TROMETAMOL
    D.3.9.1CAS number 74103-07-4
    D.3.9.4EV Substance CodeSUB02835MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name OFTAQUIX*COLL 1FL 5ML 5MG/ML
    D.2.1.1.2Name of the Marketing Authorisation holderSANTEN ITALY s.r.l.
    D.2.1.2Country which granted the Marketing AuthorisationItaly
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameOftaquix
    D.3.2Product code Oftaquix
    D.3.4Pharmaceutical form Eye drops, solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOcular use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLEVOFLOXACIN
    D.3.9.1CAS number 100986-85-4
    D.3.9.4EV Substance CodeSUB08471MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number5
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Bacterial conjunctivitis
    Bakterielle Konjunktivitis
    E.1.1.1Medical condition in easily understood language
    Bacterial conjunctivitis
    Bakterielle Bindehautentzündung
    E.1.1.2Therapeutic area Diseases [C] - Eye Diseases [C11]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10061784
    E.1.2Term Conjunctivitis bacterial
    E.1.2System Organ Class 10021881 - Infections and infestations
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To demonstrate the non-inferiority of RD03/2016 eye drops vs. levofloxacin alone in
    microbiological eradication at final visit (Day 7-9)
    Um die Nichtunterlegenheit von Augentropfen RD03 / 2016 gegenüber Levofloxacin allein in zu demonstrieren
    mikrobiologische Eradikation beim letzten Besuch (Tag 7-9)
    E.2.2Secondary objectives of the trial
    -To assess the efficacy of RD03/2016 eye drops vs. levofloxacin alone in the proportion of patients with clinical cure, i.e. resolution of cardinal signs of
    bacterial conjunctivitis, at On-Therapy (OT) visit (Day 3-4) and final visit (Day 7- 9).
    -To assess the efficacy of RD03/2016 eye drops vs. levofloxacin alone in time to clinical cure, assessed through photographs taken every 12 ± 1 hours from Day 1 to Day 7-9, using eyePRO.net (photographs on Day 0 to be taken at the earliest feasible time point post-baseline visit)
    - To assess the efficacy of RD03/2016 eye drops vs. levofloxacin alone in time to resolution of symptoms of bacterial conjunctivitis.
    - To evaluate the safety and tolerability of RD03/2016 eye drops
    - To evaluate compliance with the prescribed treatment
    For other secondary objectives see the protocol.
    - Anteil der Patienten mit klinischer Heilung (klinische Heilungsrate), d. h. Abwesenheit oder Verbesserung um mindestens eine Einheit im Vergleich zum Baseline-Wert aller Leitsymptome einer bakteriellen Konjunktivitis (Bindehautsekretion, bulbäre Bindehautinjektion und palpebrale Bindehautinjektion) beim OT-Besuch (Tag 3-4) und beim Abschlussbesuch (Tag 7-9).
    - Die Zeit bis zur klinischen Heilung nach Baseline aller Leitsymptome einer bakteriellen Konjunktivitis anhand von Fotos bewertet, die alle 12 Stunden (± 1 Std.) von Tag 0 bis Tag 7-9 mit dem eyePRO.net aufgenommen werden.
    -- Zeit bis zum vollständigen Abklingen (Fehlen) aller Symptome der bakteriellen Konjunktivitis.
    -Zur Beurteilung der Sicherheit und Verträglichkeit von RD03/2016 Augentropfen
    - Beurteilung der Compliance mit der verordneten Behandlung
    Für andere sekundäre Ziele siehe das Protokoll.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Ability of patient to consent and provide signed written informed consent
    2. Male or female aged major/= 18 year
    3. Clinical diagnosis of acute bacterial conjunctivitis with moderate/severe signs (score = 2 for each cardinal signs, i.e. bulbar conjunctival injection, palpebral conjunctival injection and conjunctival discharge, in at least one eye), not previously treated with antibiotics, steroids and nonsteroidal anti-inflammatory drugs (NSAIDs)
    4. Able and willing to follow study procedures
    5. Availability of a person (a relative or a caregiver) to be trained for the execution of the photographic documentation required by the study and for the use of eyePRO.net (see Study procedures)
    6. Willing to interrupt the use of contact lenses for the entire duration of the study
    1. Fähigkeit des Patienten zur Einwilligung und zur Abgabe einer unterzeichneten schriftlichen Einwilligungserklärung
    2. Männlich oder weiblich, Alter größer/= 18 Jahre
    3. Klinische Diagnose einer akuten bakteriellen Bindehautentzündung mit mittelschweren/schweren Anzeichen (Score = 2 für jedes Kardinalzeichen, d.h. bulbäre konjunktivale Injektion, palpebrale Injektion der Bindehaut und Bindehautausfluss an mindestens einem Auge), die zuvor nicht mit Behandlung mit Antibiotika, Steroiden und nichtsteroidalen Antirheumatika (NSAIDs)
    4. Fähig und bereit, den Studienabläufen zu folgen
    5. Verfügbarkeit einer Person (Angehörige oder Pflegeperson), die für die Durchführung der für die Studie erforderlichen Fotodokumentation und für die Nutzung von eyePRO.net zur Verfügung steht (siehe Studienabläufe)
    6. Bereitschaft, das Tragen von Kontaktlinsen für die gesamte Dauer der Studie zu unterbrechen.
    E.4Principal exclusion criteria
    1. Any acute ocular disease other than bacterial conjunctivitis
    2. Any ocular surgery (including laser treatment) in the study eye within 30 days prior to study entry
    3. Any ocular (in the study eye) or systemic antimicrobial agents administered concurrently or within 3 days prior to study entry
    4. Any ocular (in the study eye) or systemic steroids or NSAIDs administered concurrently
    5. Pathological conditions or treatments that in the opinion of the Investigator may interfere with the efficacy and/or safety evaluations of the study e.g. chronic blepharitis, glaucoma, moderate-severe dry eye)
    6. Participation in previous clinical studies if less than 5 half-lives of the Investigational Medicinal Product (IMP) used have passed
    7. Hypersensitivity to the products, other quinolones, acetylsalicylic acid and other NSAIDs (due to potential for cross-sensitivity), or their excipients
    8. Contraindications to ocular treatment with levofloxacin and/or ketorolac
    9. Pregnancy or breastfeeding
    1. Jede akute Augenerkrankung außer bakterieller Bindehautentzündung
    2. Jegliche okulare Operation (einschließlich Laserbehandlung) am Studienauge innerhalb von 30 Tagen vor vor Studienbeginn
    3. Jegliche okulare (im Studienauge) oder systemische antimikrobielle Mittel, die gleichzeitig oder innerhalb von 3 Tagen vor Studienbeginn
    4. Jegliche okulare (im Studienauge) oder systemische Steroide oder NSAIDs, die gleichzeitig verabreicht
    5. Pathologische Zustände oder Behandlungen, die nach Meinung des Prüfarztes die Wirksamkeits- und/oder Unbedenklichkeitsprüfungen der Studie beeinträchtigen könnten (z. B. chronische Blepharitis, Glaukom, mäßig-schweres trockenes Auge)
    6. Teilnahme an früheren klinischen Studien, wenn weniger als 5 Halbwertszeiten des verwendeten Prüfpräparates (IMP) vergangen sind
    7. Überempfindlichkeit gegen das Produkt, andere Chinolone, Acetylsalicylsäure und andere NSAIDs (wegen möglicher Kreuzsensitivität) oder deren Hilfsstoffe
    8. Kontraindikationen für eine okulare Behandlung mit Levofloxacin und/oder Ketorolac
    9. Schwangerschaft oder Stillen
    E.5 End points
    E.5.1Primary end point(s)
    - Proportion of patients with microbiological eradication i.e. absence/no growth of baseline pathogens assessed through bacteriological culture (calcium alginate swab of the lower conjunctiva) at final visit (Day 7-9);
    - Anteil der Patienten mit mikrobiologischer Eradikation, d. h. Abwesenheit/kein Wachstum der Ausgangserreger, bewertet durch bakteriologische Kultur (Kalziumalginatabstrich der unteren Bindehaut) bei der Abschlussuntersuchung (Tag 7-9);
    E.5.1.1Timepoint(s) of evaluation of this end point
    Days 7-9
    Tag 7-9
    E.5.2Secondary end point(s)
    -Proportion of patients with clinical cure, i.e. absence of cardinal signs of bacterial conjunctivitis (conjunctival discharge, bulbar conjunctival injectionand palpebral conjunctival injection) at OT visit (Day 3-4) and final visit (Day 7-9);
    -Time to clinical cure assessed through photographs taken every 12 ± 1 hours from Day 1 to Day 7-9, using the study smartphone and eyePRO.net;
    - Time to resolution (absence) of bacterial conjunctivitis symptoms (pain, burning/stinging, itching, tearing, foreign body sensation, photophobia and
    discomfort) recorded by the patient (0, absent; 1, present) every 12 ± 1 hours from Day 1 to Day 7-9 through an electronic patient diary;
    -Anteil der Patienten mit klinischer Heilung, d.h. Abwesenheit der Kardinalzeichen einer bakterieller Bindehautentzündung (Bindehautausfluss, bulbäre Bindehautinjektion und palpebrale konjunktivale Injektion) bei der OT-Visite (Tag 3-4) und der Abschlussvisite (Tag 7-9);
    -Zeit bis zur klinischen Heilung, bewertet durch Fotos, die alle 12 ± 1 Stunden von Tag 1 bis Tag 7-9, unter Verwendung des Studien-Smartphones und eyePRO.net;
    - Zeit bis zum Verschwinden (Abwesenheit) der Symptome der bakteriellen Bindehautentzündung (Schmerzen, Brennen/Stechen, Jucken, Tränen, Fremdkörpergefühl, Photophobie und Schmerzen, Brennen, Tränen, Fremdkörpergefühl, Photophobie und Unbehagen), aufgezeichnet vom Patienten (0, abwesend; 1, vorhanden) alle 12 ± 1 Stunden von Tag 1 bis Tag 7-9 durch ein Tag 1 bis Tag 7-9 mittels eines elektronischen Patiententagebuchs;
    E.5.2.1Timepoint(s) of evaluation of this end point
    Days 7-9
    Tag 7-9
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind Yes
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    Verblindeter Untersucher
    Blinded assessor
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA15
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Spain
    Germany
    Italy
    Portugal
    Russian Federation
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months13
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years1
    E.8.9.2In all countries concerned by the trial months9
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 126
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 126
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 200
    F.4.2.2In the whole clinical trial 252
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Standard of care
    Standardbehandlung
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2021-11-09
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2021-08-17
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    P.Date of the global end of the trial2023-06-14
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 03 20:08:30 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA